Physician profile
Ellen Davis
NPI 1275509770
$885.88
in general payments reported to CMS, 2019-2025
12 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.87 · 2022: $70.84 · 2023: $311 · 2024: $262 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.18 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $482.43 | 2022-2025 | |
| Glaxosmithkline, LLC. | $104.92 | 2021-2023 | Trelegy Ellipta, Flulaval Quadrivalent, Arexvy |
| Astellas Pharma US INC | $84.99 | 2023 | |
| Dexcom, INC. | $44.52 | 2023-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $38.33 | 2022-2024 | |
| Exact Sciences Corporation | $28.28 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $24.84 | 2024 | Rexulti |
| Shield Therapeutics INC | $16.98 | 2023 | Accrufer |
| Sumitomo Pharma America, INC. | $16.90 | 2024 | Myfembree |
| Astrazeneca Pharmaceuticals Lp | $16.46 | 2025 | Airsupra |
| Amgen INC. | $15.63 | 2025 | Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $11.60 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.